Vincerx Pharma, Inc. Overview
Pro stress-test →Vincerx Pharma, Inc., headquartered in San Diego, California, is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for patients with hematologic malignancies and other oncology indications. However, the company is in active liquidation and has announced its intention to dissolve operations.
Strategic Profile
Pro stress-test →The company's lead product candidate, pacritinib—an oral JAK2/IRAK1 inhibitor—was in-licensed from CTI BioPharma Corp. and was being evaluated for the treatment of myelofibrosis, particularly in patients with severe thrombocytopenia. Vincerx has announced its intention to delist from Nasdaq and deregister with the SEC, with plans to file a Form 25 for delisting in late April 2025.
Competitive Landscape
Pro stress-test →Vincerx was previously positioned in oncology/hematologic malignancies but is no longer operationally active. Competitors in this space include larger biopharmaceutical companies developing JAK inhibitors and targeted therapies (e.g., Incyte, Celgene).
Key facts
Founded: N/A · Headquarters: San Diego, US · Employees: N/A · Revenue: N/A · Market cap: $272K (as of June 2026)